|
FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
|
US4851332A
(en)
|
1985-04-01 |
1989-07-25 |
Sloan-Kettering Institute For Cancer Research |
Choriocarcinoma monoclonal antibodies and antibody panels
|
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
GB9012995D0
(en)
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
AU669124B2
(en)
|
1991-09-18 |
1996-05-30 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing humanized chimera antibody
|
|
US5646253A
(en)
|
1994-03-08 |
1997-07-08 |
Memorial Sloan-Kettering Cancer Center |
Recombinant human anti-LK26 antibodies
|
|
US5837821A
(en)
|
1992-11-04 |
1998-11-17 |
City Of Hope |
Antibody construct
|
|
US5504048A
(en)
|
1993-06-02 |
1996-04-02 |
Fina Technology, Inc. |
Addition of lithium compounds to Ziegler-Natta catalysts for increased molecular weight in polyolefins
|
|
US5843674A
(en)
|
1993-11-16 |
1998-12-01 |
Pola Chemical Industries Inc. |
Anti-human tyrosinase monoclonal antibody
|
|
US5635388A
(en)
|
1994-04-04 |
1997-06-03 |
Genentech, Inc. |
Agonist antibodies against the flk2/flt3 receptor and uses thereof
|
|
AU706443B2
(en)
|
1994-04-22 |
1999-06-17 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Melanoma antigens
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
WO1996022384A1
(en)
|
1995-01-18 |
1996-07-25 |
Boehringer Mannheim Gmbh |
Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
DE69726404T2
(de)
|
1996-01-05 |
2004-09-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Mesothelinantigen, verfahren und testsatz zur targetierung
|
|
DE19608769C1
(de)
|
1996-03-07 |
1997-04-10 |
Univ Eberhard Karls |
Antikörper BV10A4H2
|
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
DE69703121D1
(de)
|
1996-10-25 |
2000-10-19 |
Us Health |
Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
|
|
EP1958962A3
(en)
|
1997-06-12 |
2013-05-01 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
ATE317437T1
(de)
|
1997-12-01 |
2006-02-15 |
Us Gov Health & Human Serv |
Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung
|
|
US6183608B1
(en)
|
1998-02-05 |
2001-02-06 |
Wilbur A. Dammann |
Electrode positioning mechanism
|
|
US6803448B1
(en)
|
1998-07-22 |
2004-10-12 |
Vanderbilt University |
GBS toxin receptor
|
|
US6528481B1
(en)
|
1999-02-16 |
2003-03-04 |
The Burnam Institute |
NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
|
|
UA75049C2
(uk)
|
1999-08-17 |
2006-03-15 |
Байоджен Айдек Ма Інк. |
Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма
|
|
ATE388167T1
(de)
|
1999-09-30 |
2008-03-15 |
Kyowa Hakko Kogyo Kk |
Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
|
|
CA2406864A1
(en)
|
2000-02-24 |
2001-08-30 |
Life Technologies Corporation |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
ATE510855T1
(de)
|
2000-03-06 |
2011-06-15 |
Univ Kentucky Res Found |
Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen
|
|
US7090843B1
(en)
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
EP1456234B1
(en)
|
2001-08-23 |
2014-04-09 |
Rsr Limited |
Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto
|
|
EP1470159B1
(en)
|
2001-12-04 |
2013-08-07 |
Dana-Farber Cancer Institute, Inc. |
Antibody to latent membrane proteins and uses thereof
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
EP1590034B1
(en)
|
2002-10-07 |
2014-05-14 |
Biovalve Technologies, Inc. |
Microneedle array patch
|
|
JP4744147B2
(ja)
|
2002-11-26 |
2011-08-10 |
ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー |
アフィニティー精製抗体を用いた甲状腺刺激ホルモン受容体自己抗体の同定
|
|
WO2004087758A2
(en)
|
2003-03-26 |
2004-10-14 |
Neopharm, Inc. |
Il 13 receptor alpha 2 antibody and methods of use
|
|
CU23403A1
(es)
|
2003-04-23 |
2009-08-04 |
Centro Inmunologia Molecular |
Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
|
|
CA2530605A1
(en)
|
2003-06-27 |
2005-05-26 |
Diadexus, Inc. |
Pro104 antibody compositions and methods of use
|
|
KR20060041205A
(ko)
|
2003-07-01 |
2006-05-11 |
이뮤노메딕스, 인코오포레이티드 |
양특이성 항체들의 다가 담체들
|
|
JP2007525971A
(ja)
|
2003-08-05 |
2007-09-13 |
モルフォテック、インク． |
癌に関連する変異体細胞表面分子
|
|
JPWO2005035577A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
ガングリオシドｇｄ３に特異的に結合する抗体組成物
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US8263746B2
(en)
|
2004-02-06 |
2012-09-11 |
Morphosys Ag |
Anti-CD38 human antibodies and uses thereof
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
JP2008512352A
(ja)
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
CA2600505C
(en)
|
2005-03-10 |
2016-05-03 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
|
EP1726650A1
(en)
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
KR20080019249A
(ko)
|
2005-06-15 |
2008-03-03 |
쉐링 코포레이션 |
안정한 항체 제형
|
|
CA2619005A1
(en)
|
2005-08-10 |
2007-02-22 |
Johns Hopkins University |
Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
|
|
KR20130108481A
(ko)
|
2005-08-19 |
2013-10-02 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US8383118B2
(en)
|
2005-12-08 |
2013-02-26 |
Medarex, Inc. |
Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
WO2007109321A2
(en)
|
2006-03-20 |
2007-09-27 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
|
JP5165672B2
(ja)
|
2006-03-29 |
2013-03-21 |
キングス カレッジ ロンドン |
Ｔｓｈｒに対するアゴニスト抗体
|
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之ｃ-ｋｉｔ抗體
|
|
EP2083868A2
(en)
|
2006-10-04 |
2009-08-05 |
Københavns Universitet |
Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
|
|
FR2906808B1
(fr)
|
2006-10-10 |
2012-10-05 |
Univ Nantes |
Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
|
|
WO2008101234A2
(en)
|
2007-02-16 |
2008-08-21 |
Sloan-Kettering Institute For Cancer Research |
Anti ganglioside gd3 antibodies and uses thereof
|
|
WO2008103645A2
(en)
|
2007-02-19 |
2008-08-28 |
Wisconsin Alumni Research Foundation |
Prostate cancer and melanoma antigens
|
|
CA2682093A1
(en)
|
2007-03-29 |
2008-10-09 |
Technion Research & Development Foundation Ltd. |
Antibodies, methods and kits for diagnosing and treating melanoma
|
|
WO2008127735A1
(en)
|
2007-04-13 |
2008-10-23 |
Stemline Therapeutics, Inc. |
Il3ralpha antibody conjugates and uses thereof
|
|
JP2010190572A
(ja)
|
2007-06-01 |
2010-09-02 |
Sapporo Medical Univ |
ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬
|
|
WO2009017679A2
(en)
|
2007-07-31 |
2009-02-05 |
Merck & Co., Inc. |
Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
|
|
CA2700860C
(en)
|
2007-10-01 |
2016-07-19 |
Jonathan A. Terrett |
Human antibodies that bind mesothelin, and uses thereof
|
|
EP3103814A1
(en)
|
2007-11-26 |
2016-12-14 |
Bayer Intellectual Property GmbH |
Anti-mesothelin antibodies and uses therefor
|
|
AR071891A1
(es)
|
2008-05-30 |
2010-07-21 |
Imclone Llc |
Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
|
|
AU2009293007B2
(en)
|
2008-09-19 |
2015-10-08 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
|
|
EP2361242B1
(en)
|
2008-10-17 |
2018-08-01 |
Oryzon Genomics, S.A. |
Oxidase inhibitors and their use
|
|
EP2206723A1
(en)
|
2009-01-12 |
2010-07-14 |
Bonas, Ulla |
Modular DNA-binding domains
|
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
|
WO2010084160A1
(en)
|
2009-01-21 |
2010-07-29 |
Oryzon Genomics S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
US8492119B2
(en)
|
2009-04-27 |
2013-07-23 |
Kyowa Hakko Kirin Co., Ltd |
Antibody to human IL-3 receptor alpha chain
|
|
RU2602814C2
(ru)
|
2009-09-25 |
2016-11-20 |
Оризон Дженомикс С.А. |
Лизинспецифические ингибиторы деметилазы-1 и их применение
|
|
US8946296B2
(en)
|
2009-10-09 |
2015-02-03 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
CA2782333C
(en)
|
2009-12-02 |
2019-06-04 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
HRP20160422T1
(hr)
|
2009-12-23 |
2016-05-20 |
Synimmune Gmbh |
Protutijela protiv flt3 postupci njihove upotrebe
|
|
CN103037900B
(zh)
|
2010-02-24 |
2016-04-06 |
伊缪诺金公司 |
叶酸受体1抗体与免疫缀合物以及其用途
|
|
US9242014B2
(en)
|
2010-06-15 |
2016-01-26 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
|
|
DK3323830T3
(da)
|
2010-06-19 |
2023-09-25 |
Memorial Sloan Kettering Cancer Center |
Anti-gd2 antibodies
|
|
CA2993567C
(en)
|
2010-07-21 |
2022-06-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of a t-cell receptor gene
|
|
EP2598480B1
(en)
|
2010-07-29 |
2019-04-24 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
|
EP3467101A3
(en)
|
2010-09-08 |
2019-06-19 |
Baylor College of Medicine |
Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells
|
|
US9527805B2
(en)
|
2010-09-10 |
2016-12-27 |
Robert A. Casero |
Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
|
|
WO2012071469A2
(en)
|
2010-11-23 |
2012-05-31 |
Nevada Cancer Institute |
Histone demethylase inhibitors and uses thereof for treatment o f cancer
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
US20140163041A1
(en)
*
|
2011-02-08 |
2014-06-12 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
|
|
EA023143B1
(ru)
|
2011-03-25 |
2016-04-29 |
Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед |
Замещенный циклопропиламин в качестве ингибитора lsd1
|
|
KR20140033029A
(ko)
|
2011-04-01 |
2014-03-17 |
메모리얼 슬로안-케터링 캔서 센터 |
에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
|
|
EP2694549B1
(en)
|
2011-04-08 |
2018-08-15 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
|
AR086044A1
(es)
|
2011-05-12 |
2013-11-13 |
Imclone Llc |
Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
|
|
CA2833820C
(en)
|
2011-05-27 |
2019-10-29 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
WO2013040557A2
(en)
|
2011-09-16 |
2013-03-21 |
The Trustees Of The University Of Pennsylvania |
Rna engineered t cells for the treatment of cancer
|
|
EP3692794A1
(en)
|
2011-09-16 |
2020-08-12 |
Baylor College of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
|
DE102011114180A1
(de)
|
2011-09-22 |
2013-03-28 |
Weber Maschinenbau Gmbh Breidenbach |
Vorrichtung zum Aufschneiden von einem Lebensmittelprodukt und Vorrichtung mit einem Roboter
|
|
FR2980528B1
(fr)
|
2011-09-22 |
2013-08-30 |
IFP Energies Nouvelles |
Procede de controle de la combustion d'un moteur a combustion interne a injection directe d'essence, notamment a allumage commande
|
|
MX356344B
(es)
|
2011-10-20 |
2018-05-23 |
Oryzon Genomics Sa |
Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1.
|
|
RU2668952C2
(ru)
|
2011-10-20 |
2018-10-05 |
Оризон Дженомикс, С.А. |
(гетеро)арилциклопропиламины в качестве ингибиторов lsd1
|
|
ITMO20110270A1
(it)
|
2011-10-25 |
2013-04-26 |
Sara Caldrer |
Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
|
|
WO2013063419A2
(en)
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
US9439768B2
(en)
|
2011-12-08 |
2016-09-13 |
Imds Llc |
Glenoid vault fixation
|
|
JP6850528B2
(ja)
|
2012-02-13 |
2021-03-31 |
シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート |
二重特異性キメラ抗原受容体およびその治療的使用
|
|
WO2013126712A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
US9359447B2
(en)
|
2012-03-23 |
2016-06-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
AU2013256596A1
(en)
|
2012-05-01 |
2014-10-09 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
|
US9745381B2
(en)
|
2012-05-18 |
2017-08-29 |
Scott & White Healthcare (Swh) |
Bispecific scFv immunofusion (BIf)
|
|
EP3241902B1
(en)
|
2012-05-25 |
2018-02-28 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
WO2013192294A1
(en)
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
|
KR102530118B1
(ko)
|
2012-07-25 |
2023-05-08 |
더 브로드 인스티튜트, 인코퍼레이티드 |
유도 ｄｎａ 결합 단백질 및 게놈 교란 도구 및 이의 적용
|
|
CA2881981A1
(en)
|
2012-08-20 |
2014-02-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
US10316289B2
(en)
*
|
2012-09-06 |
2019-06-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing T memory stem cell populations
|
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
|
WO2014093718A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
CN105121648B
(zh)
|
2012-12-12 |
2021-05-07 |
布罗德研究所有限公司 |
用于序列操纵的系统、方法和优化的指导组合物的工程化
|
|
DK2931897T3
(en)
|
2012-12-12 |
2018-02-05 |
Broad Inst Inc |
CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
|
|
DK2931898T3
(en)
|
2012-12-12 |
2016-06-20 |
Massachusetts Inst Technology |
CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
AU2013359262C1
(en)
|
2012-12-12 |
2021-05-13 |
Massachusetts Institute Of Technology |
CRISPR-Cas component systems, methods and compositions for sequence manipulation
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
CA2894684A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
|
|
TW201446794A
(zh)
|
2013-02-20 |
2014-12-16 |
Novartis Ag |
利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
|
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
|
US20160046718A1
(en)
|
2013-03-14 |
2016-02-18 |
Csl Limited |
Agents that neutralize il-3 signalling and uses thereof
|
|
US20160031996A1
(en)
|
2013-03-14 |
2016-02-04 |
Csl Limited |
Anti il-3r alpha agents and uses thereof
|
|
US11332719B2
(en)
|
2013-03-15 |
2022-05-17 |
The Broad Institute, Inc. |
Recombinant virus and preparations thereof
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
AU2014248119B2
(en)
*
|
2013-04-03 |
2019-06-20 |
Memorial Sloan-Kettering Cancer Center |
Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
|
|
US11685935B2
(en)
|
2013-05-29 |
2023-06-27 |
Cellectis |
Compact scaffold of Cas9 in the type II CRISPR system
|
|
WO2014204723A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions
|
|
KR20250012194A
(ko)
|
2013-06-17 |
2025-01-23 |
더 브로드 인스티튜트, 인코퍼레이티드 |
바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
|
|
MX2015017312A
(es)
|
2013-06-17 |
2017-04-10 |
Broad Inst Inc |
Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
|
|
KR20160019553A
(ko)
|
2013-06-17 |
2016-02-19 |
더 브로드 인스티튜트, 인코퍼레이티드 |
유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
|
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
WO2014204724A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
EP3011030B1
(en)
|
2013-06-17 |
2023-11-08 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
NZ715331A
(en)
|
2013-06-19 |
2019-09-27 |
The Univ Of Utah Research Foundation |
Substituted (e)-n’-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
|
|
CA2954168C
(en)
*
|
2013-08-02 |
2023-09-19 |
The Regents Of The University Of California |
Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
|
|
US9556170B2
(en)
|
2013-08-30 |
2017-01-31 |
University Of Utah Research Foundation |
Substituted-1H-benzo[d]imidazole series compounds as lysine-specific demethylase 1 (LSD1) inhibitors
|
|
WO2015048577A2
(en)
|
2013-09-27 |
2015-04-02 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
SI3105218T1
(sl)
|
2014-02-13 |
2019-11-29 |
Incyte Corp |
Ciklopropilamini kot inhibitorji LSD1
|
|
US9527835B2
(en)
|
2014-02-13 |
2016-12-27 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
|
EP3105219B9
(en)
|
2014-02-13 |
2018-10-03 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
RU2016142476A
(ru)
*
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
AR099994A1
(es)
|
2014-04-11 |
2016-08-31 |
Takeda Pharmaceuticals Co |
Compuesto de ciclopropanamina y sus usos
|
|
US10233165B2
(en)
*
|
2014-05-30 |
2019-03-19 |
Istituto Europeo Di Oncologia S.R.L. |
Cyclopropylamine compounds as histone demethylase inhibitors
|
|
KR20170037625A
(ko)
|
2014-07-21 |
2017-04-04 |
노파르티스 아게 |
Cll-1 키메라 항원 수용체를 사용한 암의 치료
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
MX2017001079A
(es)
|
2014-07-24 |
2017-09-12 |
Bluebird Bio Inc |
Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
|
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
US10669528B2
(en)
*
|
2015-06-25 |
2020-06-02 |
Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
|
|
WO2017161001A1
(en)
*
|
2016-03-15 |
2017-09-21 |
Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion
|
|
WO2018059549A1
(en)
*
|
2016-09-30 |
2018-04-05 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|